16 research outputs found
DNA markers in oat breeding for crown rust resistance (a review)
Crown rust is the most harmful disease of oat (Avena sativa L.) around the world. The purpose of this review is to analyze and generalize the available information about DNA markers developed for oat breeding for resistance to crown rust. The review reveals the mechanisms of the A. sativa resistance to the fungus Puccinia coronata Corda f. sp. avenae Erikss. which causes crown rust disease. Special attention is paid to the race-specific resistance caused by the action of Pc genes and the nonspecific resistance controlled mainly by the loci of quantitative traits. Strategies for creating resistant genotypes and the role of molecular markers in oat breeding for crown rust resistance are discussed. Currently, research is focused mainly on the search for and development of molecular markers related to the oat race-specific resistance to P. coronata.The article presents the technological advantages and disadvantages of the existing DNA markers. KASP, TaqMan and HRM markers are currently the most promising technologies for identifying crown rust resistance genes. The validated SCAR and STS markers for the Pc39, Pc68, Pc91, Pc94 genes are recommended as the most available for implementation in practical oat breeding. The results of recent studies on identifying loci of nonspecific resistance to P. coronata are also presented. In general, the use of DNA markers has significant potential for creating oat genotypes resistant to crown rust under present-day conditions. DNA markers of various types are recommended for practical use, in particular for pyramiding genes and increasing the resistance period of new cultivars. Introduction of DNA markers into oat breeding will increase with the growth of molecular genetic data and the improvement of technologies for identifying genes and loci associated with both race-specific and nonspecific resistance of oat to P. coronata
ΠΠΎΠΊΠ°Π»ΡΠ½Π°Ρ ΡΠ΅ΡΠ΅Π±ΡΠ°Π»ΡΠ½Π°Ρ Π³ΠΈΠΏΠΎΠΏΠ΅ΡΡΡΠ·ΠΈΡ ΠΊΠ°ΠΊ ΠΏΡΠΈΡΠΈΠ½Π° ΡΠ°Π·Π²ΠΈΡΠΈΡ ΡΠΈΠΌΠΏΡΠΎΠΌΠΎΠ² ΠΈ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°ΡΡΠ΅ΡΠ½Π½ΠΎΠ³ΠΎ ΡΠΊΠ»Π΅ΡΠΎΠ·Π°
Background. Neurodegenerative processes play an important role in the development of clinical features of multiple sclerosis (MS) as well as in the progression of the disease. At the same time, neurodegenerative mechanisms of MS are not completely clear, which makes researchers pay special attention to pathogenetic aspects of the disease that have not been studied before. Previously it was shown that MS patients can have alterations in the local cerebral blood flow, however, the meaning of the detected abnormalities is still not clear.The aim of our work is to evaluate the perfusion character in the demyelinating lesions and normalappearing brain structures, and to determine their relation to clinical features of MS.Material and methods. 49 patients with relapsing-remitting and secondary progressive MS with clinical and MRI remission were included in the study. The patients underwent contrast-enhanced MR perfusion of the brain on the 3 Tesla MR-tomograph, as well as the Functional System Score, Expanded Disability Status Score and Fatigue Status Score evaluation. The data analysis included automatic construction of perfusion maps of the cerebral blood volume (CBV), cerebral blood flow (CBF) and mean transit time (MTT) values in the normal-appearing brain structures and in the demyelinating lesions and statistical analysis.Results. The received results allow to presume that variation of CBV values in MS lesions can indicate heterogeneity of processes in these lesions β from reactivation of inflammation to remyelination.Significant reduction of perfusion in nucleus lenticularis was revealed. This reduction did not depend on the severity of the disease and correlated negatively with the fatigue score. This allows to suppose that the therapy focused on brain perfusion improvement can be used as symptomatic therapy of MS. Considering the fact that regional hypoperfusion precedes the development of brain structure atrophy, it is hypothesized that the improvement of perfusion may prevent neurodegeneration in MS. The obtained findings need further investigation.Β ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΅ΠΉΡΠΎΠ΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½ΡΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΡ ΠΈΠ³ΡΠ°ΡΡ Π²Π°ΠΆΠ½ΡΡ ΡΠΎΠ»Ρ Π² ΡΠ°Π·Π²ΠΈΡΠΈΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΠΉΡΠ°ΡΡΠ΅ΡΠ½Π½ΠΎΠ³ΠΎ ΡΠΊΠ»Π΅ΡΠΎΠ·Π° (Π Π‘), Π° ΡΠ°ΠΊΠΆΠ΅ Π² ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π ΡΠΎ ΠΆΠ΅ Π²ΡΠ΅ΠΌΡ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΡΠ½Π΅ΠΉΡΠΎΠ΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠΈ ΠΏΡΠΈ Π Π‘ Π½Π΅ Π²ΠΏΠΎΠ»Π½Π΅ ΡΡΠ½Ρ, ΡΡΠΎ Π·Π°ΡΡΠ°Π²Π»ΡΠ΅Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Π΅ΠΉ ΠΎΠ±ΡΠ°ΡΠ°ΡΡ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ Π½Π°ΡΠ°Π½Π΅Π΅ Π½Π΅ ΠΈΠ·ΡΡΠ΅Π½Π½ΡΠ΅ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΡΠ»ΠΎ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Π Π‘ ΠΌΠΎΠ³ΡΡ Π½Π°Π±Π»ΡΠ΄Π°ΡΡΡΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π»ΠΎΠΊΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΡΠΎΠ²ΠΎΡΠΎΠΊΠ° Π² Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠΌ ΠΌΠΎΠ·Π³Π΅, ΠΎΠ΄Π½Π°ΠΊΠΎ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π²ΡΡΠ²Π»Π΅Π½Π½ΡΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΉ ΠΈΠ·ΡΡΠ΅Π½ΠΎ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ.Π¦Π΅Π»ΡΡ Π½Π°ΡΠ΅ΠΉ ΡΠ°Π±ΠΎΡΡ ΡΠ²Π»ΡΠ»ΠΈΡΡ ΠΎΡΠ΅Π½ΠΊΠ° ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΏΠ΅ΡΡΡΠ·ΠΈΠΈ Π² ΠΎΡΠ°Π³Π°Ρ
Π΄Π΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·Π°ΡΠΈΠΈ ΠΈ Π²Π½Π΅ΡΠ½Π΅Π½Π΅ΠΈΠ·ΠΌΠ΅Π½eΠ½Π½ΡΡ
ΡΡΡΡΠΊΡΡΡΠ°Ρ
Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΈΡ
Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΠΏΡΠΎΡΠ²Π»Π΅Π½ΠΈΡΠΌΠΈ Π Π‘.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΈΠ½ΡΠ»ΠΈ ΡΡΠ°ΡΡΠΈΠ΅ 49 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ΅ΠΌΠΈΡΡΠΈΡΡΡΡΠΈΠΌ ΠΈ Π²ΡΠΎΡΠΈΡ-Π½ΠΎ-ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΡΡΡΠΈΠΌ Π Π‘ Π² ΡΡΠ°Π΄ΠΈΠΈ ΡΠ΅ΠΌΠΈΡΡΠΈΠΈ (ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΈ ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ ΠΌΠ°Π³Π½ΠΈΡΠ½ΠΎ-ΡΠ΅Π·ΠΎΠ½Π°Π½ΡΠ½ΠΎΠΉ ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠΈΠΈ (ΠΠ Π’)), ΠΊΠΎΡΠΎΡΡΠΌ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈΡΡ ΠΠ -ΠΏΠ΅ΡΡΡΠ·ΠΈΡ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π° Ρ ΠΊΠΎΠ½ΡΡΠ°ΡΡΠ½ΡΠΌ ΡΡΠΈΠ»Π΅Π½ΠΈΠ΅ΠΌΠ½Π° ΡΠΎΠΌΠΎΠ³ΡΠ°ΡΠ΅ Ρ ΠΈΠ½Π΄ΡΠΊΡΠΈΠ΅ΠΉ ΠΌΠ°Π³Π½ΠΈΡΠ½ΠΎΠ³ΠΎ ΠΏΠΎΠ»Ρ 3 Π’Π», Π° ΡΠ°ΠΊΠΆΠ΅ ΠΎΡΠ΅Π½ΠΊΠ° ΠΏΠΎ ΡΠΊΠ°Π»Π΅ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΈΡΡΠ΅ΠΌ(FS), ΡΠ°ΡΡΠΈΡΠ΅Π½Π½ΠΎΠΉ ΡΠΊΠ°Π»Π΅ Π½Π΅ΡΡΡΠ΄ΠΎΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ (EDSS), ΡΠΊΠ°Π»Π΅ ΡΡΠΎΠΌΠ»ΡΠ΅ΠΌΠΎΡΡΠΈ (FSS). ΠΠ½Π°Π»ΠΈΠ· Π΄Π°Π½Π½ΡΡ
Π²ΠΊΠ»ΡΡΠ°Π» Π² ΡΠ΅Π±Ρ Π°Π²ΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΠ΅ ΠΏΠ΅ΡΡΡΠ·ΠΈΠΎΠ½Π½ΡΡ
ΠΊΠ°ΡΡ Π΄Π»Ρ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌ: ΠΎΠ±ΡΠ΅ΠΌ ΠΌΠΎΠ·Π³ΠΎΠ²ΠΎΠ³ΠΎΠΊΡΠΎΠ²ΠΎΡΠΎΠΊΠ° CBV, ΠΎΠ±ΡΠ΅ΠΌΠ½Π°Ρ ΡΠΊΠΎΡΠΎΡΡΡ ΠΊΡΠΎΠ²ΠΎΡΠΎΠΊΠ° CBF ΠΈ ΡΡΠ΅Π΄Π½Π΅Π΅ Π²ΡΠ΅ΠΌΡ ΡΠΈΡΠΊΡΠ»ΡΡΠΈΠΈ MTT Π² ΠΎΡΠ°Π³Π°Ρ
Π΄Π΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·Π°ΡΠΈΠΈ ΠΈ Π²Π½Π΅ΡΠ½Π΅ Π½Π΅ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΡΡ
ΡΡΡΡΠΊΡΡΡΠ°Ρ
Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠ»ΡΡΠΎΠΉ ΡΠ°Π·Π±ΡΠΎΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ CBV Π² ΠΎΡΠ°Π³Π°Ρ
ΠΌΠΎΠΆΠ΅Ρ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΠΎΠ²Π°ΡΡ ΠΎ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈΠΏΡΠΎΠΈΡΡ
ΠΎΠ΄ΡΡΠΈΡ
Π² Π½ΠΈΡ
ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² β ΠΎΡ ΡΠ΅Π°ΠΊΡΠΈΠ²Π°ΡΠΈΠΈ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ Π΄ΠΎ ΡΠ΅ΠΌΠΈΠ΅Π»ΠΈΠ½ΠΈΠ·Π°ΡΠΈΠΈ. ΠΡΡΠ²Π»Π΅Π½Π½ΠΎΠ΅ Π½Π°ΠΌΠΈΠ·Π½Π°ΡΠΈΠΌΠΎΠ΅ ΡΠ½ΠΈΠΆΠ΅Π½ΠΈΠ΅ ΠΏΠ΅ΡΡΡΠ·ΠΈΠΈ Π² Π»Π΅Π½ΡΠΈΠΊΡΠ»ΡΡΠ½ΡΡ
ΡΠ΄ΡΠ°Ρ
Π²Π½Π΅ Π·Π°Π²ΠΈΡΠΈΠΌΠΎΡΡΠΈ ΠΎΡ ΡΡΠΆΠ΅ΡΡΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ, ΠΊΠΎΡΠΎΡΠΎΠ΅ ΠΎΡΡΠΈΡΠ°ΡΠ΅Π»ΡΠ½ΠΎ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΠΎΠ²Π°Π»ΠΎ Ρ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΡΡΡΡ ΡΡΠΎΠΌΠ»ΡΠ΅ΠΌΠΎΡΡΠΈ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡΡ, ΡΡΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ, Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½Π°Ρ Π½Π° ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΏΠ΅ΡΡΡΠ·ΠΈΠΈ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°, ΠΌΠΎΠΆΠ΅Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡΡΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ΡΠΈΠΌΠΏΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π Π‘. Π£ΡΠΈΡΡΠ²Π°Ρ ΡΠΎ, ΡΡΠΎ ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½Π°Ρ Π³ΠΈΠΏΠΎΠΏΠ΅ΡΡΡΠ·ΠΈΡ ΠΎΠΏΠ΅ΡΠ΅ΠΆΠ°Π΅Ρ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅Π°ΡΡΠΎΡΠΈΠΈ, ΠΌΡ ΡΡΠΈΡΠ°Π΅ΠΌ, ΡΡΠΎ Π»Π΅ΡΠ΅Π½ΠΈΠ΅, Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Π½ΠΎΠ΅ Π½Π° ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΏΠ΅ΡΡΡΠ·ΠΈΠΈ, ΡΠΏΠΎΡΠΎΠ±Π½ΠΎ ΠΏΡΠ΅Π΄ΠΎΡΠ²ΡΠ°ΡΠ°ΡΡΡΠ°Π·Π²ΠΈΡΠΈΠ΅ Π½Π΅ΠΉΡΠΎΠ΄Π΅Π³Π΅Π½Π΅ΡΠ°ΡΠΈΠ²Π½ΡΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΏΡΠΈ Π Π‘, ΡΡΠΎ ΡΡΠ΅Π±ΡΠ΅Ρ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ
CLIPPERS. ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΈ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΠ΅ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ
CLIPPERS (Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) is a rare inflammatory disease of the central nervous system, during which the pons of the brain is damaged. This disease was described for the first time in 2010 by S.J. Pittock et.al. At present, there have been around 50 described cases of the disease. Up to the present moment, there are difficulties diagnosing this disease. In the article, a literature review and three clinical cases are presented. Furthermore, the necessity of further research is shown for improving the accuracy and specificity of the diagnostic criteria, as well as for defining biomarkers and developing algorithms of effective therapy.CLIPPERS (Chronic lymphocytic inflammation with pontine perivascular enhancement responsive tosteroids) β Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π»ΠΈΠΌΡΠΎΡΠΈΡΠ°ΡΠ½ΠΎΠ΅ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΠ΅ Ρ ΠΏΠΎΡΠ°ΠΆΠ΅Π½ΠΈΠ΅ΠΌ ΠΌΠΎΡΡΠ°, ΠΊΠΎΠ½ΡΡΠ°ΡΡΠ½ΡΠΌ ΡΡΠΈΠ»Π΅Π½ΠΈΠ΅ΠΌΠΏΠ΅ΡΠΈΠ²Π°ΡΠΊΡΠ»ΡΡΠ½ΡΡ
ΠΏΡΠΎΡΡΡΠ°Π½ΡΡΠ², ΠΎΡΠ²Π΅ΡΠ°ΡΡΠ΅Π΅ Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡ Π³Π»ΡΠΊΠΎΠΊΠΎΡΡΠΈΠΊΠΎΡΡΠ΅ΡΠΎΠΈΠ΄Π½ΡΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ,ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠΎΠ±ΠΎΠΉ ΡΠ΅Π΄ΠΊΠΎΠ΅ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ ΡΠ΅Π½ΡΡΠ°Π»ΡΠ½ΠΎΠΉ Π½Π΅ΡΠ²Π½ΠΎΠΉ ΡΠΈΡΡΠ΅ΠΌΡ, Π²ΠΎΠ²Π»Π΅ΠΊΠ°ΡΡΠ΅Π΅ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΌΠΎΡΡ Π³ΠΎΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΌΠΎΠ·Π³Π°. ΠΠΏΠ΅ΡΠ²ΡΠ΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΎ ΠΎΠΏΠΈΡΠ°Π½ΠΎ Π² 2010 Π³. S.J. Pittock ΠΈΡΠΎΠ°Π²Ρ. Π Π½Π°ΡΡΠΎΡΡΠ΅Π΅ Π²ΡΠ΅ΠΌΡ Π² Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΠ΅ ΠΎΠΏΠΈΡΠ°Π½ΠΎ ΠΎΠΊΠΎΠ»ΠΎ 50 ΡΠ»ΡΡΠ°Π΅Π². ΠΠ°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ Π΄ΠΎ Π½Π°ΡΡΠΎΡΡΠ΅Π³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈΠ²ΡΠ·ΡΠ²Π°Π΅Ρ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠΎΠ±Π»Π΅ΠΌΡ. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠΈΠ²Π΅Π΄Π΅Π½ ΠΊΡΠ°ΡΠΊΠΈΠΉ ΠΎΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ ΠΈ ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΡΠ΅Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ ΡΡΠ΅Ρ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ»ΡΡΠ°Π΅Π². ΠΠΎΠΊΠ°Π·Π°Π½Π° Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π΄Π»ΡΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΠΈ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π², ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π±ΠΈΠΎΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΈΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ Π°Π»Π³ΠΎΡΠΈΡΠΌΠΎΠ² ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Regional cerebral hypoperfusion as a cause of symptoms and progression of multiple sclerosis
Background. Neurodegenerative processes play an important role in the development of clinical features of multiple sclerosis (MS) as well as in the progression of the disease. At the same time, neurodegenerative mechanisms of MS are not completely clear, which makes researchers pay special attention to pathogenetic aspects of the disease that have not been studied before. Previously it was shown that MS patients can have alterations in the local cerebral blood flow, however, the meaning of the detected abnormalities is still not clear.The aim of our work is to evaluate the perfusion character in the demyelinating lesions and normalappearing brain structures, and to determine their relation to clinical features of MS.Material and methods. 49 patients with relapsing-remitting and secondary progressive MS with clinical and MRI remission were included in the study. The patients underwent contrast-enhanced MR perfusion of the brain on the 3 Tesla MR-tomograph, as well as the Functional System Score, Expanded Disability Status Score and Fatigue Status Score evaluation. The data analysis included automatic construction of perfusion maps of the cerebral blood volume (CBV), cerebral blood flow (CBF) and mean transit time (MTT) values in the normal-appearing brain structures and in the demyelinating lesions and statistical analysis.Results. The received results allow to presume that variation of CBV values in MS lesions can indicate heterogeneity of processes in these lesions β from reactivation of inflammation to remyelination.Significant reduction of perfusion in nucleus lenticularis was revealed. This reduction did not depend on the severity of the disease and correlated negatively with the fatigue score. This allows to suppose that the therapy focused on brain perfusion improvement can be used as symptomatic therapy of MS. Considering the fact that regional hypoperfusion precedes the development of brain structure atrophy, it is hypothesized that the improvement of perfusion may prevent neurodegeneration in MS. The obtained findings need further investigation
CLIPPERS. Three clinical cases and review
CLIPPERS (Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids) is a rare inflammatory disease of the central nervous system, during which the pons of the brain is damaged. This disease was described for the first time in 2010 by S.J. Pittock et.al. At present, there have been around 50 described cases of the disease. Up to the present moment, there are difficulties diagnosing this disease. In the article, a literature review and three clinical cases are presented. Furthermore, the necessity of further research is shown for improving the accuracy and specificity of the diagnostic criteria, as well as for defining biomarkers and developing algorithms of effective therapy
Copper-substituted tricalcium phosphates
Β© 2016, Pleiades Publishing, Ltd.Copper-substituted tricalcium phosphates (CuTCP) with different copper contents were developed using precipitation of copper-containing amorphous calcium phosphates (ACP) from salt solutions followed by heat treatment. Porous CuTCP ceramic was obtained using negative replicas. Using a set of investigation methods (powder X-ray diffraction, IR spectroscopy, ESR spectroscopy, and scanning electron microscopy), all copper-substituted tricalcium phosphates were found to have the whitlockite structure with copper incorporated in TCP in the 2+ oxidation state. The resulting material is promising for the use in regenerative medicine owing to higher solubility in body fluids compared with TCP and combination of bactericidal properties and the lack of cytotoxicity
PVP-stabilized tungsten oxide nanoparticles: pH sensitive anti-cancer platform with high cytotoxicity
Photochromic tungsten oxide (WO3) nanoparticles stabilized by polyvinylpyrrolidone (PVP) were synthesized to evaluate their potential for biomedical applications. PVP-stabilized tungsten oxide nanoparticles demonstrated a highly selective cytotoxic effect on normal and cancer cells in vitro. WO3 nanoparticles were found to induce substantial cell death in osteosarcoma cells (MNNG/HOS cell line) with a half-maximal inhibitory concentration (IC50) of 5 mg/mL, while producing no, or only minor, toxicity in healthy human mesenchymal stem cells (hMSc). WO3 nanoparticles induced intracellular oxidative stress, which led to apoptosis type cell death. The selective anti-cancer effects of WO3 nanoparticles are due to the pH sensitivity of tungsten oxide and its capability of reactive oxygen species (ROS) generation, which is expressed in the modulation of genes involved in reactive oxygen species metabolism, mitochondrial dysfunction, and apoptosis
Copper-substituted tricalcium phosphates
Β© 2016, Pleiades Publishing, Ltd.Copper-substituted tricalcium phosphates (CuTCP) with different copper contents were developed using precipitation of copper-containing amorphous calcium phosphates (ACP) from salt solutions followed by heat treatment. Porous CuTCP ceramic was obtained using negative replicas. Using a set of investigation methods (powder X-ray diffraction, IR spectroscopy, ESR spectroscopy, and scanning electron microscopy), all copper-substituted tricalcium phosphates were found to have the whitlockite structure with copper incorporated in TCP in the 2+ oxidation state. The resulting material is promising for the use in regenerative medicine owing to higher solubility in body fluids compared with TCP and combination of bactericidal properties and the lack of cytotoxicity
EFFECT OF NEURODEGENERATIVE CHANGES IN THE BRAIN ON THE FORMATION OF THE DISEASE CLINICAL PICTURE IN PATIENTS WITH MULTIPLE SCLEROSIS
The aim of the study was to determine the relationship of global and regional cerebral atrophy and volume of demyelination lesions in the brain with a clinical picture in patients with multiple sclerosis (MS). The study involved 55 patients with MS. Control group included 22 healthy volunteers. Patients were divided into groups according to the severity of disability, the type and duration of disease. Assessment of general and regional atrophy was performed by post-process volumetric segmentation of MRI data, which was acquired at 3T Philips Achieva scanner. The post-processing was done with the FreeSurfer software. It is shown that in MS patients brain atrophy develops both by means of gray matter (including the cortex and subcortical structures), and white matter, along with demyelination. Global and regional atrophy is associated with the severity of disability of patients according to EDSS scale, but not with the duration and type of the disease. Neurodegenerative changes of brain structures evolve with different rates, have different intensity and determine the set of symptoms of neurological impairment and severity of disability, which indicates the presence of certain patterns of the process of atrophy in the brain, forming the clinical picture of the disease